Mutational Study of RAS Subfamily 2CE2 Domain and Fosfestrol as an Ideal Drug Candidate against NSCLC

Lung cancer is a deadly disease that is prevalent as one of the largest contributor to higher mortality rates. Most commonly EGFR is the widely studied factor in almost 90 % of the cases that are considered in the epidemiological study of lung cancer. The present work deals primarily in considering KRAS as an important factor for impending cancer deaths, particularly NSCLC and Designing a potent drug Fosfesterol as a potent target for the same. The basis of the study includes the analysis of a few drug candidates and their activity against NSCLC in comparison to Fosfestrol. Fosfestrol proved to be an effective drug candidate which is ascertained by protein blockage due to correct docking. So fosfestrol may be considered as potent drug against NSCLC for further clinical trials.